{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-054933","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.625302+00:00","generated_at":"2026-06-03T04:07:09.950140+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx Q1 revenue $10.8M (+35% YoY); net loss $22.2M; FY guidance $50-53M","bullets":["Q1 revenue $10.8M (+35% YoY); US HF revenue $9.7M (+43%); active implanting centers 190 (+56% YoY).","Net loss $22.2M ($1.04/shr) vs $11.4M ($0.55) prior year; SG&A $28.3M (+84%) from stock-based comp modification for former CEO.","Full-year 2024 revenue guidance $50-53M; Q2 2024 revenue expected $11.3-12.3M.","Kevin Hykes appointed CEO Feb 12; BeAT-HF data published in European Journal of Heart Failure.","Compensation Committee approved $50k bonus to Paul Verrastro for management transition support."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-054933","json":"https://secwatch.observer/filing/0001104659-24-054933.json","markdown":"https://secwatch.observer/filing/0001104659-24-054933.md","text":"https://secwatch.observer/filing/0001104659-24-054933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465924054933/0001104659-24-054933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465924054933/tm2412998d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:07:09.950140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb242b00b6dad1d5c20395400bbe65094b563e79","claim":"CVRx, Inc. reported the first quarter of 2024 results: revenue $10.8 million, net income $22.2 million, or $1.04 per share, EPS $1.04 per share. Guidance reaffirmed.","evidence_excerpt":"cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights · Total revenue for the first quarter 2024 was $ 10.8 million, an increase of 35 % over the prior year quarter · U.S. Heart Failure (HF) revenue for the first quarter of 2024 was $ 9.7 million, an increase of 43 % over the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465924054933/0001104659-24-054933-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"$10.8 million"},{"label":"Net income","value":"$22.2 million, or $1.04 per share"},{"label":"EPS","value":"$1.04 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}